AMENDMENT NO. 3 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • November 9th, 2017 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment No. 3”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 and December 10, 2014 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of October 26, 2017.
COLLABORATION AND OPTION AGREEMENT between IMMUNOGEN, INC. and JAZZ PHARMACEUTICALS IRELAND LIMITED dated August 28, 2017Collaboration and Option Agreement • November 9th, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
This Collaboration and Option Agreement (this “Agreement”) is made effective as of August 28, 2017 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Jazz Pharmaceuticals Ireland Limited, a corporation organized under the laws of Ireland (“Jazz”), with its principal place of business at Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. ImmunoGen and Jazz are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties.”
